Amphastar Pharmaceuticals, Inc. is a recognized specialty pharmaceutical company that uses state-of-the-art, cGMP compliant facilities to develop, manufacture, and market injectable and inhalation products. Amphastar and its subsidiaries each have their own distinct focus that they skillfully bring together to meet the varied needs of the pharmaceutical industry. Its products include Enoxaparin Sodium Injection, Cortrosyn, Amphadase, Emergency Syringes in Luer-Jet, Lidocaine, Naloxone, and Phytonadione Injection.

Type
Public
HQ
Rancho Cucamonga, US
Founded
1996
Size (employees)
1,541 (est)
Amphastar Pharmaceuticals was founded in 1996 and is headquartered in Rancho Cucamonga, US
Report incorrect company information

Amphastar Pharmaceuticals Office Locations

Amphastar Pharmaceuticals has an office in Rancho Cucamonga
Rancho Cucamonga, US (HQ)
11570 6th St
Show all (1)
Report incorrect company information

Amphastar Pharmaceuticals Financials and Metrics

Amphastar Pharmaceuticals Financials

Amphastar Pharmaceuticals's revenue was reported to be $240.18 m in FY, 2017
USD

Revenue (Q1, 2018)

58.4 m

Gross profit (Q1, 2018)

17.1 m

Gross profit margin (Q1, 2018), %

29.2%

Net income (Q1, 2018)

(7.2 m)

EBIT (Q1, 2018)

(9.9 m)

Market capitalization (15-May-2018)

725.8 m

Closing share price (15-May-2018)

15.6

Cash (31-Mar-2018)

54.5 m
Amphastar Pharmaceuticals's current market capitalization is $725.8 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Revenue

210.5 m251.5 m255.2 m240.2 m

Revenue growth, %

20%1%

Cost of goods sold

159.2 m174.2 m151 m149.4 m

Gross profit

51.3 m77.3 m104.2 m90.8 m
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Revenue

49 m59.7 m56.9 m53.9 m63.9 m59.4 m68 m64.2 m56.7 m65.2 m58.4 m

Cost of goods sold

34 m47.9 m43.6 m40.5 m46.3 m34.5 m36.3 m36.6 m33.8 m38.4 m41.3 m

Gross profit

15 m11.8 m13.3 m13.3 m17.6 m24.9 m31.7 m27.6 m22.8 m26.7 m17.1 m

Gross profit Margin, %

31%20%23%25%28%42%47%43%40%41%29%
Annual
usdY, 2012Y, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

50.2 m53.6 m67.8 m66.1 m72.4 m65.6 m

Accounts Receivable

22.9 m33.2 m26.8 m36 m

Inventories

118.4 m63.6 m

Current Assets

198 m175.9 m184.1 m187.8 m
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Cash

64.1 m72.9 m68.6 m74.5 m76.8 m82.5 m54.5 m

Accounts Receivable

18.6 m26.6 m21.7 m19.8 m25 m23.1 m23.1 m26.6 m25.9 m24.1 m31.9 m

Inventories

106 m88.1 m84.9 m80.2 m72.4 m82.2 m88.3 m90.7 m78.1 m74.5 m62.8 m

Current Assets

214.2 m215.2 m202.6 m203.9 m199.1 m173.4 m181.3 m190.2 m191.4 m193.6 m174 m
Annual
usdFY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(10.7 m)(2.8 m)10.5 m4.5 m

Depreciation and Amortization

12 m12.6 m

Inventories

9.1 m(9.7 m)18.7 m

Accounts Payable

7 m6.7 m
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Net Income

(1.2 m)(5.4 m)(665 k)(6.6 m)(3 m)2.5 m6.9 m3.9 m893 k(7.2 m)

Depreciation and Amortization

3.2 m

Inventories

1.4 m

Accounts Payable

17.8 m10 m18.9 m18.4 m12.3 m18.6 m18.8 m13.4 m19.3 m2.9 m
USDY, 2018

Financial Leverage

1.4 x
Show all financial metrics

Amphastar Pharmaceuticals Operating Metrics

FY, 2016

Facilities

5

Products

19
Show all operating metrics
Report incorrect company information